Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.
University of Rochester Medical CenterSep 19 2024 Research ers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia , a common condition related to cancer that involves weight loss and muscle wasting .
The results of the randomized phase 2 clinical trial, which included187 individuals who experienced cachexia with lung, pancreatic, or colorectal cancer, were reported in the New England Journal of Medicine on Sept. 14, 2024. Richard Dunne, MD, MS, a Wilmot Cancer Institute oncologist and cachexia expert was part of the large group of investigators who ran the nationwide clinical trial.
Cachexia involves loss of appetite and weight, muscle-wasting, fatigue, and weakness. It affects more than 50 percent of people who have cancer, and currently there are no FDA-approved treatments. Scientists discovered that a drug, ponsegromab, blocks a hormone known as GDF-15 that regulates appetite and body weight. The patients in the trial had elevated levels of GDF-15, a primary driver of cachexia. Ponsegromab is a type of drug known as a monoclonal antibody, and in this trial, it improved many aspects of cachexia and its symptoms. Side effects were minimal, Dunne said, and in fact ponsegromab appeared to be safer than common appetite stimulants used by cachexia patients.
Journal reference:Groarke, J. D., et al. Ponsegromab for the Treatment of Cancer Cachexia. New England Journal of Medicine. doi.org/10.1056/NEJMoa2409515.
Cancer Clinical Trial Colorectal Colorectal Cancer Medicine Muscle Muscle Wasting Research Weight Loss
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Researchers show novel drug rescues memory loss in Alzheimer's mouse modelIn a recent development in Alzheimer's disease research, Auburn University scientists have studied a new drug, troriluzole, that can prevent brain changes leading to memory loss and cognitive decline in a mouse model of the disease.
Read more »
Public health researchers find decriminalization of drug possession was not associated with Oregon overdose spikeWhen overdose rates spiked in Oregon in 2021 after the state decriminalized low-level drug possession, blame quickly turned to the new state law. But a new study by researchers at the Brown University School of Public Health implicates another factor: the introduction of fentanyl into Oregon's unregulated drug market.
Read more »
Advanced drug screening: A microphysiological system to assess drug transport and nephrotoxicityDeveloping advanced drug screening tools is crucial for the advancement of personalized medicine and the creation of more effective treatments. One organ receiving particular attention in this area is the kidney.
Read more »
How the Parkinson's drug Levodopa causes psychiatric complications similar to drug abuseResearchers at Karolinska Institutet have identified a mechanism responsible for a serious psychiatric complication caused by dopamine replacement therapy in Parkinson's disease. The results of these findings were recently published in Molecular Psychiatry.
Read more »
Fentanyl still deadliest drug in Florida as overall deaths decline and another synthetic drug risesThe number of Floridians who died from drugs last year decreased across the state, but one synthetic drug was noticeably on the rise and fentanyl is still the deadliest drug of all, according to a statewide report released this summer.
Read more »
Men on common prescription drug put unborn babies at risk, warns UK drug regulator...null
Read more »